Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that ha… Read more
Market Cap & Net Worth: Aileron Therapeutics Inc (ALRN)
Aileron Therapeutics Inc (NASDAQ:ALRN) has a market capitalization of $45.72 Million ($45.72 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22173 globally and #7870 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aileron Therapeutics Inc's stock price $2.11 by its total outstanding shares 21665900 (21.67 Million).
Aileron Therapeutics Inc Market Cap History: 2017 to 2025
Aileron Therapeutics Inc's market capitalization history from 2017 to 2025. Data shows change from $4.57 Billion to $45.72 Million (-45.88% CAGR).
Index Memberships
Aileron Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1972 of 3165 |
Weight: Aileron Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aileron Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aileron Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALRN by Market Capitalization
Companies near Aileron Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Aileron Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aileron Therapeutics Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Aileron Therapeutics Inc's market cap moved from $4.57 Billion to $ 45.72 Million, with a yearly change of -45.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $45.72 Million | -8.26% |
| 2024 | $49.83 Million | -24.56% |
| 2023 | $66.05 Million | +28.63% |
| 2022 | $51.35 Million | -78.95% |
| 2021 | $243.91 Million | -45.88% |
| 2020 | $450.65 Million | +81.50% |
| 2019 | $248.29 Million | -31.79% |
| 2018 | $363.99 Million | -92.03% |
| 2017 | $4.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Jan 9th, 2026 the market cap of Aileron Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $45.72 Million USD |
| MoneyControl | $45.72 Million USD |
| MarketWatch | $45.72 Million USD |
| marketcap.company | $45.72 Million USD |
| Reuters | $45.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.